148 related articles for article (PubMed ID: 32131978)
61. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.
Mathé EA; Nguyen GH; Bowman ED; Zhao Y; Budhu A; Schetter AJ; Braun R; Reimers M; Kumamoto K; Hughes D; Altorki NK; Casson AG; Liu CG; Wang XW; Yanaihara N; Hagiwara N; Dannenberg AJ; Miyashita M; Croce CM; Harris CC
Clin Cancer Res; 2009 Oct; 15(19):6192-200. PubMed ID: 19789312
[TBL] [Abstract][Full Text] [Related]
62. Circulating serum exosomal
Lu X; Lu J; Wang S; Zhang Y; Ding Y; Shen X; Jing R; Ju S; Chen H; Cong H
Future Oncol; 2021 Mar; 17(8):907-919. PubMed ID: 33533649
[TBL] [Abstract][Full Text] [Related]
63. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
64. Role of DNA content determination by image analysis in confirmation of dysplasia in Barrett's esophagus.
Khan M; Bui HX; del Rosario A; Abdulla M; Ballouk F; Sim YJ; Ross JS
Mod Pathol; 1994 Feb; 7(2):169-74. PubMed ID: 8008738
[TBL] [Abstract][Full Text] [Related]
65. Circulating MicroRNAs in Relation to Esophageal Adenocarcinoma Diagnosis and Survival.
Petrick JL; Pfeiffer RM; Liao LM; Abnet CC; Wu X; Gammon MD; Vaughan TL; Cook MB
Dig Dis Sci; 2021 Nov; 66(11):3831-3841. PubMed ID: 33403483
[TBL] [Abstract][Full Text] [Related]
66. MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.
Causin RL; da Silva LS; Evangelista AF; Leal LF; Souza KCB; Pessôa-Pereira D; Matsushita GM; Reis RM; Fregnani JHTG; Marques MMC
Biomed Res Int; 2021; 2021():6650966. PubMed ID: 33954190
[TBL] [Abstract][Full Text] [Related]
67. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
[TBL] [Abstract][Full Text] [Related]
68. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
Jankowski J; Hopwood D; Pringle R; Wormsley KG
Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
[TBL] [Abstract][Full Text] [Related]
69. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
70. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
71. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma.
Zheng G; Du L; Yang X; Zhang X; Wang L; Yang Y; Li J; Wang C
Br J Cancer; 2014 Nov; 111(10):1985-92. PubMed ID: 25233400
[TBL] [Abstract][Full Text] [Related]
72. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
[TBL] [Abstract][Full Text] [Related]
73. Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers.
Jusoh AR; Mohan SV; Lu Ping T; Tengku Din TADAAB; Haron J; Romli RC; Jaafar H; Nafi SN; Tuan Salwani TI; Yahya MM
Asian Pac J Cancer Prev; 2021 May; 22(5):1375-1381. PubMed ID: 34048164
[TBL] [Abstract][Full Text] [Related]
74. Serum miR-210-3p as a Potential Noninvasive Biomarker of Lung Adenocarcinoma: A Preliminary Study.
Świtlik WZ; Karbownik MS; Suwalski M; Kozak J; Szemraj J
Genet Test Mol Biomarkers; 2019 May; 23(5):353-358. PubMed ID: 30950648
[No Abstract] [Full Text] [Related]
75. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
[TBL] [Abstract][Full Text] [Related]
76. Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett's Esophagus.
Waterhouse DJ; Januszewicz W; Ali S; Fitzgerald RC; di Pietro M; Bohndiek SE
Cancer Res; 2021 Jun; 81(12):3415-3425. PubMed ID: 34039635
[TBL] [Abstract][Full Text] [Related]
77.
Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
[No Abstract] [Full Text] [Related]
78. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
79. Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma.
Pavlov K; Kluiver J; Meijer C; Boersma-van Ek W; Kruyt FAE; Karrenbeld A; Kleibeuker JH; Peters FTM; van den Berg A
J Gastrointest Oncol; 2018 Dec; 9(6):1150-1156. PubMed ID: 30603135
[TBL] [Abstract][Full Text] [Related]
80. A predictive Bayesian network that risk stratifies patients undergoing Barrett's surveillance for personalized risk of developing malignancy.
Bradley A; Sami S; N G H; Macleod A; Prasanth M; Zafar M; Hemadasa N; Neagle G; Rosindell I; Apollos J
PLoS One; 2020; 15(10):e0240620. PubMed ID: 33045017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
